


FORM PTO 1300 (REV 5-00)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NUMBER 2001_1026A	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371				U.S. APPLICATION NO. (If known, enter) 09/914265 NEW	
International Application No. PCT/JP00/07451		International Filing Date October 25, 2000		Priority Date Claimed December 27, 1999	
Title of Invention EXTERNAL SKIN PATCH					
Applicant(s) For DO/EO/US Keiko YAMASAKI, Mitsuji AKAZAWA, Jutaro SHUDO, Keiji NOZAKI					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). ATTACHMENT A 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input checked="" type="checkbox"/> An unexecuted oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). ATTACHMENT B 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). Items 11. to 14. below concern other document(s) or information included: 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. ATTACHMENT C 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. ATTACHMENT D <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> Other items or information:					

THE COMMISSIONER IS AUTHORIZED
 TO CHARGE ANY DEFICIENCY IN THE
 FEE FOR THIS PAPER TO DEPOSIT
 ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. 09/914265 NEW		INTERNATIONAL APPLICATION NO. PCT/JP00/07451		ATTORNEY'S DOCKET NO. 2001_1026A					
15. [X] The following fees are submitted BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International Search Report has been prepared by the EPO or JPO \$ 860.00 International preliminary examination fee not paid at USPTO but international search paid to USPTO \$ 710.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee paid at USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%;">CALCULATIONS</th> <th style="width: 50%;">PTO USE ONLY</th> </tr> <tr> <td style="height: 100px; vertical-align: bottom;">\$860.00</td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY	\$860.00	
CALCULATIONS	PTO USE ONLY								
\$860.00									
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00					
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$					
Claims	Number Filed	Number Extra	Rate						
Total Claims	-20 =		X \$18.00	\$					
Independent Claims	-3 =		X \$80.00	\$					
Multiple dependent claim(s) (if applicable)				+	\$270.00 \$				
TOTAL OF ABOVE CALCULATIONS =				\$860.00					
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$					
SUBTOTAL =				\$860.00					
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$					
TOTAL NATIONAL FEE =				\$860.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$					
TOTAL FEES ENCLOSED =				\$860.00					
				Amount to be refunded	\$				
				Amount to be charged	\$				
a. [X] A check in the amount of \$860.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
19. CORRESPONDENCE ADDRESS <div style="text-align: center;">  000513 PATENT TRADEMARK OFFICE </div>			By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr., Registration No. 33,367 WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250 August 24, 2001						

[CHECK NO. 46120]

[2001_1026A]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Keiko YAMASAKI et al. : Attn: BOX PCT
Serial No. NEW : Docket No. 2001_1026A
Filed August 24, 2001 :

EXTERNAL SKIN PATCH
[Corresponding to PCT/JP00/07451
Filed October 25, 2000]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Prior to calculating the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, immediately after the title, please insert:

This application is a 371 of PCT/JP00/07451 filed October 25, 2000.

IN THE CLAIMS

Please amend the claims as follows:

3. (Amended) An external skin patch according to claim 1, in which the nonsteroidal antiphlogistic analgesic agent comprises one or more kinds of compounds selected from the group consisting of indomethacin, ketoprofen, piroxicam, felbinac, bufexamac, suprofen, flurbiprofen, diclofenac, ibuprofen and pharmaceutically acceptable salts thereof.

4. (Amended) An external skin patch according to claim 1, in which the drug-containing base contains the local anesthetic in an amount of 0.1 - 50% by weight.

5. (Amended) An external skin patch according to claim 1, in which the drug-containing base contains the nonsteroidal antiphlogistic analgesic agent in an amount of 0.05 - 10% by weight.

Kindly add the following new claim:

6. An external skin patch according to claim 1, in which the local anesthetic comprises one or more kinds of compounds selected from the group consisting of lidocaine and pharmaceutically acceptable salts thereof, and the nonsteroidal antiphlogistic analgesic agent comprises one or more kinds of compounds selected from the group consisting of indomethacin, felbinac, diclofenac and pharmaceutically acceptable salts thereof.

REMARKS

The specification has been amended to reflect the 371 status.

In addition, the multiple dependencies of the claims have been removed, and new claim 6 has been added corresponding to new claim 6 presented during prosecution of the international application.

Attached to this amendment is a copy of a brief explanation about claim 6 which was submitted under Article 19 during prosecution of the international application.


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version with markings to show changes made**".

Favorable action on the merits is solicited.

Respectfully submitted,

Keiko YAMASAKI et al.

By



Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 24, 2001

09/914265
518 Rec'd PCT/PTO 24 AUG 2001

- 1 -

DESCRIPTION

EXTERNAL SKIN PATCH

Technical Field

✓ This application is a 371 of PCT/JP00/01451 Filed October 25, 2001.

The present invention relates to antiphlogistic
5 analgesic external preparations. In particular, it relates
to an external skin patch having greatly improved
antiphlogistic analgesic effects which has a drug reservoir
layer comprising a drug-containing base containing an
adhesive gel base which contains a water soluble polymeric
10 material, a crosslinking agent, water and a humectant as its
essential components, and a local anesthetic and a
nonsteroidal antiphlogistic analgesic agent as medicinal
components.

Background Art

15 At present, many kinds of nonsteroidal antiphlogistic
analgesic agents having excellent anti-inflammatory,
analgesic, and antipyretic actions, have been developed,
and widely used against rheumatic disease, a postoperative
pain or the pain after removal of a suture. Such a
20 nonsteroidal antiphlogistic analgesic agent has been
originally developed as an oral preparation, and has been
employed as a useful therapeutic agent, however, the oral
administration of such a nonsteroidal antiphlogistic
analgesic agent may cause adverse effects such as
25 gastrointestinal tract disorder etc.

- 23 -

CLAIMS

1. An external skin patch, comprising a substrate and a drug reservoir layer coated on the substrate, in which the drug reservoir layer comprises a drug-containing base
5 containing an adhesive gel base which contains a water soluble polymeric material, a crosslinking agent, water and a humectant as essential components, and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal components.

10 2. An external skin patch according to claim 1, in which the local anesthetic comprises one or more kinds of compounds selected from the group consisting of tetracaine, procaine, dibucaine, lidocaine, benzocaine, xylocaine, and
~~pharmaceutically acceptable salts thereof.~~

✓ 15 3. ^(Amended) An external skin patch according to claim 1 ~~or~~
~~claim 2,~~ in which the nonsteroidal antiphlogistic analgesic agent comprises one or more kinds of compounds selected from the group consisting of indomethacin, ketoprofen, piroxicam, felbinac, bufexamac, suprofen, flurbiprofen, diclofenac,
20 ibuprofen and pharmaceutically acceptable salts thereof.

✓ 4. ^(Amended) An external skin patch according to ~~any of claims 1~~
~~to 3,~~ in which the drug-containing base contains the local anesthetic in an amount of 0.1 - 50 % by weight.

✓ 5. ^(Amended) An external skin patch according to ~~any of claims 1~~
25 ~~to 4,~~ in which the drug-containing base contains the

- 1 -

Explanation Under S19(1) of Treaty

Claim 6 of this application specifies and defines an optimum combination of a local anesthetic and a nonsteroidal antiphlogistic analgesic agent which are components of the external skin patch of the present invention.

External preparation of nonsteroidal antiphlogistic analgesic agent alone is not effective for the remedy from pains which are caused by patchion of nerve, nerve stimulus, bleeding, edema etc., and which are accompanied by arthorheumatism, arthrosis or low back pain. Likewise, external preparation of a local anesthetic alone is ineffective. Such ineffectiveness is attributable to the following reasons. Namely, these external preparations for suppressing pains are locally-administrated remedies. The nonsteroidal antiphlogistic analgesic agent and the local anesthetic agent have different action mechanisms in regard to anti-inflammatory and pain sensation suppressing effects. Each of these agents, when used alone, cannot be an effective remedy against composite pains of the kind described above.

The cited document "JP, 11-171768, A" discloses an invention concerning an external preparation containing indomethacin. Paragraph [0014] of this cited document states that the indomethacin-containing external preparation

may contain a local anesthetic agent such as lidocaine. Another cited document, "JP, 06-145053, A" discloses an invention pertaining to an external skin patch having an adhesive layer essentially containing indomethacin. Paragraph [0019] of this document states that the external skin patch may contain a local anesthetic agent such as lidocaine as required.

The disclosure of each of the cited documents pertains is directed to the stability and release characteristic of the indomethacin alone, and fails to teach or suggest the composite pain suppressing effect against the diseases of the kind described, which is obtainable solely through combining a nonsteroidal antiphlogistic analgesic agent and a local anesthetic agent. The present invention is based on a finding of the fact that a high remedy effect on the diseases of the kind described is achieved by simultaneous local administration of a nonsteroidal antiphlogistic analgesic agent and a local anesthetic agent. The dermal administration systems of the nonsteroidal antiphlogistic analgesic agent and a local anesthetic agent are entirely different from those disclosed in the cited documents.

- 1 -

DESCRIPTION

EXTERNAL SKIN PATCH

Technical Field

The present invention relates to antiphlogistic analgesic external preparations. In particular, it relates to an external skin patch having greatly improved antiphlogistic analgesic effects which has a drug reservoir layer comprising a drug-containing base containing an adhesive gel base which contains a water soluble polymeric material, a crosslinking agent, water and a humectant as its essential components, and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal components.

Background Art

At present, many kinds of nonsteroidal antiphlogistic analgesic agents having excellent anti-inflammatory, analgesic, and antipyretic actions, have been developed, and widely used against rheumatic disease, a postoperative pain or the pain after removal of a suture. Such a nonsteroidal antiphlogistic analgesic agent has been originally developed as an oral preparation, and has been employed as a useful therapeutic agent, however, the oral administration of such a nonsteroidal antiphlogistic analgesic agent may cause adverse effects such as gastrointestinal tract disorder etc.

On the other hand, an external preparation in the form of an ointment or a liquid drug has been developed for the treatment of arthrorheumatism, arthrosis deformans or low back pain, in order to change the administration route, so that the drug can be selectively delivered to the affected part, and the adverse effects caused from the oral administration, such as gastrointestinal tract disorder etc, can be alleviated. However, it is difficult to keep the applied dose or the applied area of these ointments and liquid drugs constant, and these ointments and liquid drugs often present a problem with use, i.e. the applied part becomes sticky, or these ointments and liquid drugs adhere to the clothes etc.

In contrast to this, patches are a preparation having the similar efficacy as those of the ointments and the liquid drugs. The patches are applied to a skin, and allow the drug to be transdermally absorbed into the body. The patches have various merits which are not owned by the ointments, such as accuracy of the applied dose, simplicity of the administration, and the hermeticity of the preparation applied to the affected part. In addition to these, the patches allow the drug to be continuously absorbed, thereby they show a prolonged action, therefore people has great expectations for the usefulness of the patches.

Presently, external skin patches containing three kinds of nonsteroidal agent (i.e. indomethacin, ketoprofen and flurbiprofen) have been on the market and their usefulness have been appreciated, as disclosed in the Japanese

Unexamined Patent Application Publications No.2-212423, No.4-82828, No.8-319243, and No.9-124466.

At present, however, it is still difficult to provide analgesic effects against chronic pain coming from chronic arthrorheumatism, arthrosis deformans, low back pain and the like, even with these preparations. The reasons are believed to be as follows; the pain in the chronic arthrorheumatism, the arthrosis deformans and the low back pain are the somatic deep pain and the deep tissue causing such deep pain is not directly exposed to the external irritations, therefore the pain arises from fasciatonus or spasm caused by inflammation, patchion of nerve, nerve stimulus, bleeding, and edema etc. Either a local anesthetic or a nonsteroidal antiphlogistic analgesic agent when given alone for these symptoms does not work on both the inflammatory site and the peripheral nervous system, thereby the effect is limited. This is because, the local anesthetic reversibly anesthetizing a peripheral sensory nerve axis cylinder to lower or disappear the sensation of pain etc, and the nonsteroidal antiphlogistic analgesic agent working on a synapse on the path of pain, not on the sensory nerve

fiber, to render the patient unaware of pain, have different mechanism of action on the pain respectively.

Accordingly, in the state of the art, a satisfactory external skin patch which has high painkilling effect for pains accompanied by inflammation, such as chronic arthrorheumatism, arthrosis deformans or low back pain, has not yet been developed.

Disclosure of Invention

A purpose of the present invention is to provide an external skin patch having improved painkilling effect for pains accompanied by inflammation, such as chronic arthrorheumatism, arthrosis deformans or low back pain.

As a result of extensive study carried out to solve the above-mentioned problem, the present inventors have found that the external skin patch in which a material comprising an adhesive gel base containing a water soluble polymeric material, a crosslinking agent, water and a humectant as essential components blended with both a local anesthetic and a nonsteroidal antiphlogistic analgesic agent is coated on a substrate, has excellent drug release controlling function, and allows the drug to be transdermally absorbed for an extended length of time, and shows remarkable pain killing effect on the pain accompanied by inflammation such as chronic arthrorheumatism, arthrosis deformans or low back pain by the anti-inflammatory effect as well as the local

analgesic effect, and came to achieve this invention.

Accordingly, the present invention provides an external skin patch, comprising a substrate and a drug reservoir layer coated on the substrate, in which the drug reservoir
5 layer comprises a drug-containing base comprising an adhesive gel base containing a water soluble polymeric material, a crosslinking agent, water and a humectant as essential components, and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal
10 components.

The present invention provides the above-mentioned external skin patch, in which the local anesthetic comprises one or more kinds of compounds selected from the group consisting of tetracaine, procaine, dibucaine, lidocaine,
15 benzocaine, xylocaine, and pharmaceutically acceptable salts thereof.

The present invention provides the above-mentioned external skin patch, in which the nonsteroidal antiphlogistic analgesic agent comprises one or more kinds
20 of compounds selected from the group consisting of indomethacin, ketoprofen, piroxicam, felbinac, bufexamac, suprofen, flurbiprofen, diclofenac, ibuprofen and pharmaceutically acceptable salts thereof.

The present invention provides any of the above-
25 mentioned external skin patches in which the drug-containing

base contains the local anesthetic in an amount of 0.1 - 50 % by weight.

The present invention provides any of the above-mentioned external skin patches in which the drug-containing base contains the nonsteroidal antiphlogistic analgesic agent in an amount of 0.05 - 10 % by weight.

The present invention will be explained in detail.

An external skin patch according to the present invention has a substrate and a drug reservoir layer coated on the substrate.

(1) Substrates

The substrate employed for the external skin patch according to the present invention, can be any substrate usually employed in the art for an external skin patch.

Examples of such a substrate include polyester, polyvinyl chloride, lint, nylon, an unwoven fabric or a composite material thereof. If necessary, a liner of a suitable material (such as a polypropylene film, polyethylene film, polyurethane film and the like) can be attached to the surface of the drug reservoir layer in order to prevent evaporation of the water therefrom and to protect the layer. The thickness of the substrate is not particularly limited and can be appropriately chosen depending on the applications.

(2) Drug reservoir layer

The drug reservoir layer of the external skin patch of the present invention comprises a drug-containing base comprising an adhesive gel base and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal components.

<Adhesive gel base>

The adhesive gel base employed according to the present invention contains a water soluble polymeric substance, a crosslinking agent, water and a humectant as essential components.

Examples of the above-mentioned water soluble polymeric substance include gelatin, starch, agar, mannan, alginic acid, polyacrylic acid, a salt of polyacrylic acid, dextrin, methyl cellulose, hydroxypropyl cellulose, methyl cellulose sodium, carboxymethyl cellulose, carboxymethyl cellulose sodium, polyvinyl alcohol, polyvinyl pyrrolidone, methyl vinyl ether-maleic anhydride copolymer, gum Arabic, gum tragacanth, karaya gum, locust bean gum, and the like.

These water soluble polymeric materials are mainly employed such that the other materials employed in the adhesive gel base can exhibit their physical properities and desired properties can be obtained. These materials can be used alone or in admixture of two or more kinds.

The amount of the above-mentioned water soluble polymeric materials added to the adhesive gel base is

preferably 0.5 - 50 % by weight, more preferably 5 - 25 % by weight. The content of the water soluble polymeric material falling within the above-mentioned range is preferable since the water retaining properties, adhesion and feel on use are improved.

As the crosslinking agent according to the present invention, both organic and inorganic crosslinking agents can be employed, however, an aluminum compound is preferable. Examples of the aluminum compound include aluminum hydroxide, aluminum chloride, aluminum silicate hydrate, synthetic aluminum silicate, dry aluminum hydroxide gel, aluminum acetate, aluminum lactate, aluminum stearate, magnesium aluminometasilicate, dihydroxyaluminum aminoacetate etc. These crosslinking agents can impart an appropriate strength to the gel as an initial property, prevent the strength of the gel from lowering, as they carry out efficient crosslinking with the polymeric material, maintain the form retaining properties, improve the stability of the properties of the preparations with time, and improve the workability and feel on use. These crosslinking agents can be used alone or in admixture of two or more kinds.

The amount of the above-mentioned crosslinking agents in the adhesive gel base is preferably 0.001 - 10 % by weight, more preferably it is 0.01 - 5 % by weight.

As water according to the present invention, purified

water, sterilized water or ion-exchanged water is preferably used. Water is employed for swelling the corneal layer of epidermis and for improving the permeation of the drug, and the amount of the water added to the adhesive gel base is preferably selected to be within a range of from 10 to 80 % by weight, more preferably of from 20 to 60 % by weight.

Examples of the humectant according to the present invention include polyhydric alcohols such as ethylene glycol, diethylene glycol, polyethylene glycol, glycerin, sorbitol, multitol, propylene glycol, and 1,3-butylene glycol, saccharides such as sodium hyaluronate, and a superabsorbent resin such as starch-acrylonitrile graft body, starch-acrylic acid graft body, starch-styrene sulfonic acid graft body, starch-vinyl sulfonic acid graft body, polyvinyl alcohol crosslinked body, polyethylene glycol diacrylate crosslinked body, acrylic acid-vinyl acetate saponified product and the like. These humectants are employed to maintain the water content in the adhesive gel base at a constant level, so that the adverse effect on the drug releasing rate to the skin, resulting from the evaporation of the water from the obtained external skin patch during its storage or use, can be reduced. These humectants can be used alone or in admixture of two or more kinds.

The amount of the above-mentioned humectants used in the adhesive gel base is preferably 0.01 - 80 % by weight,

more preferably it is 1 - 60 % by weight.

<Local anesthetic>

Preferable local anesthetics employed according to the present invention include, but not limited to, a compound
5 selected from the group consisting of tetracaine, procaine, dibucaine, lidocaine, benzocaine, xylocaine, and pharmaceutically acceptable salts thereof. These can be used alone or in admixture of two or more kinds.

The amount of the local anesthetic contained in the drug-containing base is preferably 0.1 - 50 % by weight,
10 more preferably 2 - 20 % by weight based on the total amount of the drug-containing base. The amount of the local anesthetic below this range is not preferable due to insufficient efficacy, but the amount above this range is
15 not preferable either, since the same effect is obtained with the danger of a side effect.

<Nonsteroidal antiphlogistic analgesic agent>

Preferable examples of the nonsteroidal antiphlogistic analgesic agents employed according to the present invention
20 include indomethacin, ketoprofen, piroxicam, felbinac, bufexamac, suprofen, flurbiprofen, diclofenac, ibuprofen and pharmaceutically acceptable salts thereof, however, the nonsteroidal antiphlogistic analgesic agents employed according to the present invention are not limited to these.
25 These can be used alone or in admixture of two or more kinds.

The content of the above-mentioned nonsteroidal antiphlogistic analgesic agent in the drug-containing base is preferably 0.05 - 10 % by weight, more preferably it is 0.2 - 5 % by weight based on the total amount of the drug-
5 containing base. The amount of the nonsteroidal antiphlogistic analgesic agent below the above-mentioned range is not preferable due to insufficient efficacy, but an amount above the range is not preferable either, since the same effect is obtained with the danger of a side effect.

10 <Optional component>

The adhesive gel base employed according to the present invention may include various additional components employed in an ordinary adhesive gel base, in addition to the essential components, i.e. the water soluble polymer, the
15 crosslinking agent, water and the humectant. Examples of such optional component include, for example, solvents such as N-methyl-2-pyrrolidone, crotamiton, N,N-dimethyl acetamide, benzyl alcohol, mint oil, and isopropyl myristate; aliphatic acids such as stearic acid and oleic acid; various
20 surfactants including nonionic surfactants, anionic surfactants, cationic surfactants and amphoteric surfactants such as polyoxyethylene sorbitan fatty ester, polyoxyethylene hardened castor oil, polyglycerin fatty ester; ethers such as polyoxyethylene isocetyl ether; and other
25 antiseptics, stabilizers, perfumes, coloring matters,

powders, absorbing assistants, and pH adjusters etc.

As medicinal components, in addition to the above-mentioned local anesthetics and the nonsteroidal antiphlogistic analgesic agents, other analgesic,

5 antipruritic, astringent, antiphlogistic agents such as salicylic acid, and a derivative thereof, camphor, capsicum extract, 1-menthol and the like can be used in combination.

The amount of these variety of additives can be suitably decided depending on the types of each product.

10 These agents can be subjected to an ordinary process and formulated into an external skin patch.

<Preparation of a drug-containing base>

The drug-containing base according to the present invention comprises the above-mentioned adhesive gel base

15 with which the local anesthetic and the nonsteroidal antiphlogistic analgesic agent are blended as medicinal components. The preparation of the above-mentioned drug-containing base is not particularly limited, and the constituents of the adhesive gel base, i.e. the water
20 soluble polymeric material, the crosslinking agent, water, the humectant, the optional components employed if desired, and effective amounts of the local anesthetic and the nonsteroidal antiphlogistic analgesic agent are
25 appropriately mixed, and homogeneously kneaded. The order of the blending is not particularly limited. The medicinal

components can be previously dissolved in an appropriate solvent then mixed.

(3) External skin patch

The external skin patch according to the present invention can be produced by spreading and coating the drug-containing base prepared according to the above-mentioned process on an appropriate substrate to form a drug reservoir layer. The amount of the drug-containing base coated is usually within a range of from 200 to 2000 g/m², preferably of from 500 to 1500 g/m².

Best Mode for Carrying Out the Invention

The present invention will be further illustrated with reference to the following Examples, however, this invention is not limited to these Examples. All the proportions shown in Examples and Comparative Examples are % by weight.

EXAMPLE 1

A drug-containing base having a formulation given in the Table 1 below was prepared. More specifically, lidocaine was dissolved in propylene glycol and sodium diclofenac was dissolved in N-methyl-2-pyrrolidone. These solutions were kneaded with other reagents shown in Table 1 until the mixture showed homogeneity to give a drug-containing base. The drug-containing base thus obtained was spread on a nonwoven fabric at 1000 g/m², and a polypropylene liner was attached to it then it was cut to a

size of 10 x 14 cm² to give an external skin patch.

Table 1

Ingredient	Proportion
Sodium diclofenac	1
Lidocaine	5
Propylene glycol	10
N-methyl-2-pyrrolidone	5
70% sorbitol solution	20
Sodium polyacrylate	5
Carboxymethyl cellulose sodium	4
Dry aluminum hydroxide gel	0.3
Tartaric acid	2.5
Kaolin	5
Purified water	the remainder
Total	100

EXAMPLE 2

A drug-containing base having a formulation given in the Table 2 below was prepared. More specifically, felbinac was dissolved in crotamiton and benzocaine was dissolved in propylene glycol. These solutions were kneaded with other reagents shown in Table 2 until the mixture showed homogeneity to give a drug-containing base. The drug-containing base thus obtained was spread on a nonwoven fabric at 1000 g/m², and a polypropylene liner was attached to it then it was cut to a size of 10 x 14 cm² to give an external skin patch.

Table 2

Ingredient	Proportion
Felbinac	0.5
Benzocaine	7
Propylene glycol	5
Glycerin	10
70% sorbitol solution	15
Sodium polyacrylate	5
Carboxymethyl cellulose sodium	5
Dihydroxy aluminum acetate	0.2
Diethanol amine	0.5
Crotamiton	2
Tartaric acid	1.5
Purified water	the remainder
Total	100

EXAMPLE 3

A drug-containing base having a formulation given in the Table 3 below was prepared. More specifically,

5 indomethacin was dissolved in crotamiton and dibucaine hydrochloride was dissolved in purified water in an amount of 10 % by weight. These solutions were kneaded with other reagents shown in Table 3 until the mixture showed homogeneity to give a drug-containing base. The drug-
10 containing base thus obtained was spread on a nonwoven fabric at 1000 g/m², and a polypropylene liner was attached to it then it was cut to a size of 10 x 14 cm² to give an external skin patch.

Table 3

Ingredient	Proportion
Indomethacin	0.6
Dibucaïne Hydrochloride	6
Propylene glycol	5
Crotamiton	2
Glycerin	10
70% sorbitol solution	15
Sodium polyacrylate	5
Polyacrylic acid	2
Carboxymethyl cellulose sodium	4
Magnesium aluminometasilicate	0.3
Tartaric acid	1.7
Sodium edetate	0.1
Purified water	the remainder
Total	100

EXAMPLE 4

A drug-containing base having a formulation given in the Table 4 below was prepared. More specifically,

- 5 ketoprofen was dissolved in crotamiton and tetracaine hydrochloride was dissolved in purified water in an amount of 15 % by weight. These solutions were kneaded with other reagents shown in Table 4 until the mixture showed
- homogeneity to give a drug-containing base. The drug-
- 10 containing base thus obtained was spread on a nonwoven fabric at 1000 g/m², and a polypropylene liner was attached to it then it was cut to a size of 10 x 14 cm² to give an

external skin patch.

Table 4

Ingredient	Proportion
Ketoprofen	0.5
Tetracaine hydrochloride	8
Crotamiton	2
Glycerin	5
70% sorbitol solution	15
Sodium polyacrylate	2
Polyacrylic acid	5
Carboxymethyl cellulose sodium	5
Dihydroxy aluminum acetate	0.2
Tartaric acid	1.5
Sodium edetate	0.1
Purified water	the remainder
Total	100

EXAMPLE 5

5 A drug-containing base having a formulation given in
the Table 5 below was prepared. More specifically,
flurbiprofen was dissolved in N-methyl-2-pyrrolidone, and
procaine hydrochloride was dissolved in purified water in an
amount of 20 % by weight. These solutions were kneaded with
10 other reagents shown in Table 5 until the mixture showed
homogeneity to give a drug-containing base. The drug-
containing base thus obtained was spread on a nonwoven
fabric at 1000 g/m², and a polypropylene liner was attached

to it then it was cut to a size of 10 x 14 cm² to give an external skin patch.

Table 5

Ingredient	Proportion
Flurbiprofen	0.4
Procaine hydrochloride	10
Propylene glycol	5
N-methyl-2-pyrrolidone	5
Glycerin	10
70% sorbitol solution	15
Sodium polyacrylate	6
Polyacrylic acid	2
Carboxymethyl cellulose sodium	4
Dry aluminum hydroxide gel	0.3
Tartaric acid	1.5
Sodium edetate	0.1
Purified water	the remainder
Total	100

EXAMPLE 6

5 A drug-containing base having a formulation given in
the Table 6 below was prepared. More specifically,
buxefamac was dissolved in N-methyl-2-pyrrolidone and
xylocaine was dissolved in purified water in an amount of
10% by weight. These solutions were kneaded with other
10 reagents shown in Table 6 until the mixture showed
homogeneity to give a drug-containing base. The drug-
containing base thus obtained was spread on a nonwoven

fabric at 1000 g/m², and a polypropylene liner was attached to it then it was cut to a size of 10 x 14 cm² to give an external skin patch.

Table 6

Ingredient	Proportion
Bufexamac	0.6
Xylocaine	8
Propylene glycol	5
N-methyl-2-pyrrolidone	5
Glycerin	12
70% sorbitol solution	14
Sodium polyacrylate	5
Polyacrylic acid	3
Carboxymethyl cellulose sodium	5
Dry aluminum hydroxide gel	0.3
Tartaric acid	1.2
Sodium edetate	0.1
Purified water	the remainder
Total	100

5 Comparative Example 1

An external skin patch was prepared in the same production process employed in Example 1 except that the same amount of purified water was blended instead of sodium diclofenac.

10 Comparative Example 2

An external skin patch was prepared in the same production process employed in Example 1 except that the

same amount of purified water was blended instead of lidocaine.

Comparative Example 3

5 An external skin patch was prepared in the same production process employed in Example 3 except that the same amount of purified water was blended instead of indomethacin.

Comparative Example 4

10 An external skin patch was prepared in the same production process employed in Example 3 except that the same amount of purified water was blended instead of dibucaine hydrochloride.

Test Example

15 The external skin patches obtained in Examples 1 and 3 and Comparative Examples 1 - 4 were administered randomly to volunteers each having low back pain (i.e. plastered on the affected part) and an organoleptic examination was carried out. The duration of the administration was 12 hours a day and the test was carried out for 7 days. After the test, 20 volunteers rated the results on a 1-to-4 scale ("complete remission", "effective", "unchanged" and "aggravation".) After 1 week of drug withdrawal, the same test was repeated until all the external skin patches were evaluated. The results are given in Table 7.

Table 7

	Ex. 1	Ex. 3	C.Ex.1	C.Ex.2	C.Ex.3	C.Ex.4
Complete Remission	7	5	0	3	0	0
Effective	2	5	2	5	3	7
Unchanged	1	0	8	2	6	3
Aggra- vation	0	0	0	0	1	0

As shown above, the amelioration ratio (effective or higher) of the external skin patches of Examples 1 and 3, and Comparative Examples 1 - 4 after 1 week was respectively 90% (9/10), 100% (10/10), 20% (2/10), 80% (8/10), 30% (3/10), and 70% (7/10), and the ratio of the Complete Remission was respectively 70% (7/10), 50% (5/10), 0% (0/10), 30% (3/10), 0% (0/10), and 0% (0/10).

This shows that the external skin patch in which a local anesthetic as well as a nonsteroidal antiphlogistic analgesic agent are contained (Examples 1 and 3) are superior to the external skin patches including either a local anesthetic or a nonsteroidal antiphlogistic analgesic agent alone (Comparative Examples 1 - 4). In other words, the effectiveness of the external skin patch according to the present invention in which both the local anesthetic and the nonsteroidal antiphlogistic analgesic agent are contained in combination was confirmed.

Industrial Applicability

An external skin patch according to the present invention comprising a drug reservoir layer coated on a substrate, the drug reservoir layer comprising an adhesive gel base containing a water soluble polymeric material, a crosslinking agent, water and a humectant as essential components, and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal components, shows remarkable pain killing effect on the pain accompanied by inflammation such as chronic arthrorheumatism, arthrosis deformans or low back pain.

CLAIMS

1. An external skin patch, comprising a substrate and a drug reservoir layer coated on the substrate, in which the drug reservoir layer comprises a drug-containing base
5 containing an adhesive gel base which contains a water soluble polymeric material, a crosslinking agent, water and a humectant as essential components, and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal components.

10 2. An external skin patch according to claim 1, in which the local anesthetic comprises one or more kinds of compounds selected from the group consisting of tetracaine, procaine, dibucaine, lidocaine, benzocaine, xylocaine, and pharmaceutically acceptable salts thereof.

15 3. An external skin patch according to claim 1 or claim 2, in which the nonsteroidal antiphlogistic analgesic agent comprises one or more kinds of compounds selected from the group consisting of indomethacin, ketoprofen, piroxicam, felbinac, bufexamac, suprofen, flurbiprofen, diclofenac,
20 ibuprofen and pharmaceutically acceptable salts thereof.

4. An external skin patch according to any of claims 1 to 3, in which the drug-containing base contains the local anesthetic in an amount of 0.1 - 50 % by weight.

25 5. An external skin patch according to any of claims 1 to 4, in which the drug-containing base contains the

2



DECLARATION AND OATH OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original () Supplemental () Substitute (X) PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: EXTERNAL SKIN PATCH

of which is described and claimed in:

() the attached specification, or

(X) the specification in application Serial No. NEW filed August 24, 2001, and with amendments through _____, or(X) the specification in International Application No. PCT/JP00/07451, filed October 25, 2000, and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	11-368718	December 27, 1999	Yes


I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from Takano & Partner as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys

and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.



Direct Correspondence to Customer No:



000513

PATENT TRADEMARK OFFICE

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.
2033 "K" Street, N.W., Suite 800
Washington, D.C. 20006-1021

Phone: (202) 721-8200
Fax: (202) 721-8250

Full Name of First Inventor	FAMILY NAME YAMASAKI	FIRST GIVEN NAME Keiko	SECOND GIVEN NAME
Residence & Citizenship	CITY Kagawa	STATE OR COUNTRY Japan JPX	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 313-31, Machida, Ochi-cho, Okawa-gun, Kagawa, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Second Inventor	FAMILY NAME AKAZAWA	FIRST GIVEN NAME Mitsuji	SECOND GIVEN NAME
Residence & Citizenship	CITY Kagawa	STATE OR COUNTRY Japan JPX	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 1472-4, Higashiyama, Shirotori-cho, Okawa-gun, Kagawa, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Third Inventor	FAMILY NAME SHUDO	FIRST GIVEN NAME Jutaro	SECOND GIVEN NAME
Residence & Citizenship	CITY Kagawa	STATE OR COUNTRY Japan JPX	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 114, 1-1, Sanbonmatsu, Ochi-cho, Okawa-gun, Kagawa, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fourth Inventor	FAMILY NAME NOZAKI	FIRST GIVEN NAME Keiji	SECOND GIVEN NAME
Residence & Citizenship	CITY Tokyo	STATE OR COUNTRY Japan JPX	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS Asakashion-sangenjaya 305, 1-5-11, Sangenjaya, Setagaya-ku, Tokyo, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Keiko Yamasaki Date 8/7
 Keiko YAMASAKI
 2nd Inventor Mitsuji Akazawa Date 8/7
 Mitsuji AKAZAWA
 3rd Inventor Jutaro Shudo Date 8/20
 Jutaro SHUDO
 4th Inventor Keiji Nozaki Date 8/20
 Keiji NOZAKI
 5th Inventor _____ Date _____
 6th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U.S. Application Serial No. NEW Filing Date _____

Applicant Reference Number FP-002-PCT-US Atty Docket No. 2001_1026A

Title of Invention _____